Company news: Janssen, Zeno Group
Janssen is reassuming ex-US marketing rights for its Caeylx/Doxil cancer treatment. Merck & Co. has marketed the drug abroad since 1996. That deal expires at the end of the year, and marketing rights for the drug will revert to Janssen subsidiary ALZA Corp. Janssen currently markets the product in the US, Japan and Israel under the Doxil brand.
Zeno Group named former Burson-Marsteller healthcare head Ame Wadler managing director for health and strategic planning. Wadler joins the firm from MWW Group, where she was EVP, chief management officer. Before that, she was chief strategic officer at Burson and chairman of the global healthcare practice, having joined that firm from Zeno Group parent Edelman.